|Bid||2.5700 x 900|
|Ask||2.6100 x 1100|
|Day's range||2.5000 - 2.6650|
|52-week range||1.6000 - 5.4100|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||31 Oct 2014|
|1y target est||18.50|
Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) is possibly approaching a major achievement in its business, so we would...
Participants on today's call are Evan Loh, M.D., chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer. Michael Bigham, executive chairman, and I will also be available for questions.
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?